Hansa Biopharma AB (publ) (HNSBF) Q3 2026 Earnings Call Transcript

Hansa Biopharma AB (publ) (HNSBF) reported Q3 2026 earnings. Revenue increased by 25% year-over-year, driven by strong demand for the company's immunotherapies.

The company also announced positive clinical trial results for its lead product candidate, imlifidase.

Want to stay up to date with the world events at sea or at home?